Paragon Bioservices Hires Mark Adams as VP of Project Management
BALTIMORE, Aug. 10, 2016/PRNewswire/ — Paragon Bioservices, Inc., a leader in the manufacturing of biopharmaceuticals and vaccines, announced today that Mark Adams has joined the company as Vice President of Project Management. Mr. Adams will be responsible for directing Paragon’s Project Management team.
Mr. Adams comes to Paragon with a wealth of knowledge and over 30 years of industry experience at leading companies such as Shire Human Genetic Therapies, Genzyme Transgenics, Lonza Biologics and, most recently, at Cytovance Biologics. As VP of Program Management for Cytovance, Mark established a Program Management team that led cross-functional project teams, driving milestone deliverables for over 25 client process development and GMP manufacturing programs. He has extensive knowledge and experience in biological drug development. Mr. Adams holds a M.Sc. in Biochemistry from University College, Cork, Ireland.
“we are very please to welcome Mark to Paragon’s management team. He brings a proven track record of accomplishment in building project maangement systems and teams that drive commercial growth. We welcome his leadership and experience and are confident he will significantly strengthen our operation,” said Pete Buzy, President of Paragon.
About Paragon Bioservices, Inc.
Paragon Bioservices is a private-equity backed contract development and manufacturing organization (CDMO) whose focus is the development and manufacturing of biopharmaceuticals. The company provides research services, process development and cGMP manufacturing. Paragon functions as a translational bridge — from the research bench through manufacturing of APIs and finished drug product for Phase I/II clinical trials. Paragon’s aim is to build strong client partnerships for development and manufacturing, focusing on transformative technologies, including oncology immunotherapies (CAR-T cell therapies and oncolytic viruses), new generation vaccines (VLPs) and gene therapies (AAV). Paragon’s cGMP facilities include microbial and mammalian suites, aseptic fill-finish and fully-segregated virus facilities.
Philip Wills, VP Business Development